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INTRODUCTION 
Around fourty percent of new chemical entities developed by the pharmaceutical 
industry are poorly soluble or lipophilic compounds, which result poor oral bioavailability, 
high intra and inter subject variability and lack of dose proportionality.  
Oral delivery route is the most convenient route for drug administration to achieve 
desired therapeutic effects and the greatest degree of patient compliance, especially for chronic 
condition diseases. Despite some clinical oral formulations have been developed, their low oral 
bioavailability is still a major hurdle, leading to challenges for pharmaceutical manufacturers 
to design delivery systems that can provide improved pharmacokinetic profiles and therapeutic 
responses. Currently, many efforts such as efflux pump inhibitors, permeation enhancers and 
drug nanonization, have been made to overcome the challenges of low oral bioavailability 
resulting from low drug solubility, poor permeation and enzymatic degradation, which limiting 
drug effective delivery. 
Advantages of oral delivery systems 
 
Oral administration is the most widely accepted and preferred route for 
pharmaceuticals, due to its high convenience and better patient compliance. Oral 
administration of drugs can avoid hospitalization, sterile manufacturing and trained personnel 
assistance, so reducing the cost of the health treatment. Pharmaco-economic analyses were 
performed in clinical trials to evaluate the economic effectiveness of various oral drugs and to 
make a contrast with the cost of infusion administration. 
Challenges in the oral drug delivery 
Regardless of many advantages, the development of oral delivery route still represents 
a great challenge owing to peculiar physicochemical properties of lipophilic drug candidates, 
and physiological barriers such as gastrointestinal instability, pre-systemic metabolism and 
efflux pump. Upon oral administration, lipophilic drug in a dosage form is easily ingested by 
patients, travels in the GIT passing through an extremely various environment. When drug 
transits from a strong acidic pH in stomach to basic environment of the intestine, it encounters 
harsh pH changes, but also different digestive enzymes and the resident micro flora.  
After the digestive journey, only a fraction of dose is available to systemic circulation for the 
execution of therapeutic response. In view of this, the principal challenges to the oral delivery 
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are classified into physicochemical properties of drugs and physiological barriers posed by 
human body (Figure 1). 
 
 
 
 
 
 
Figure 1: Schematic representation of the various challenges 
 to the oral delivery of drugs. 
 
Biopharmaceutical drug classification system 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Biopharmaceutical drug classification system 
 
Class I includes drugs that are water soluble and gastrointestinal tract permeable. This class 
does not suffer from absorption or permeation problems that may affect oral drug 
bioavailability. While classes II, III and IV contain drugs having problems in solubility and/or  
Permeability that may reflect on their bioavailability in the blood after the drug is taken orally. 
Classes II, III and IV form approximately 80% of the drugs available in the market. 
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Solubility of drug substances 
A plenty of organic materials are poorly soluble in water. The poorly water-soluble 
drugs are typical examples. Poor solubility of a drug is in most cases associated with poor 
bioavailability. Furthermore, in drug discovery, about 40% of new drug candidates display 
poor solubility in water, which leads to low bioavailability, erratic absorption, high intra-
subject and inter-subject variability and lack of dose proportionality. From a physicochemical 
point of view, poor aqueous solubility and low dissolution rate are the major factors that affect 
oral delivery of many existing lipophilic drugs. Improving the drug solubility might only solve 
one aspect of the problem but it is a starting point to design efficient pharmaceutical 
formulations. 
Gastrointestinal transit 
 
Human digestive system is complicatedly designed to safely, selectively, and 
effectively absorb as many nutrients as possible from our diet. In the case of drug delivery, 
after the oral administration, drug candidates have to reach final absorption site – intestine. 
However, the gastrointestinal tract (GIT) presents various chemical and enzymatic barriers that 
affect delivery of drugs. During the drug transit, the pH of the GI tract lumen rises from the 
strongly acidic (pH 1.0–2.0) in the stomach, to 5.0–6.0 in the duodenum, to basic (pH 7.0-9.0) 
in the jejunum. On the other hand, variety of enzymes that include lipases and proteases also 
function to initiate foodstuff digestion and destroy unwanted pathogens and toxins. 
Furthermore, the gastrointestinal transit time is another factor that significantly affects oral 
bioavailability and efficacy of many drugs.  
Many efforts have been done to enhance the duration for absorption, like the dosage form 
mucoadhesive. The use of mucoadhesives can increase local drug concentrations for absorption 
enhancement, improve the efficiency for prolonging drug resistance time, and in some cases 
restrict absorption to a specific site in the intestine. So far, various types of approaches have 
been successfully developed to extend the gastrointestinal transit time, further to improve the 
intestinal permeability and to enhance the oral bioavailability. 
Approaches for enhancement of oral bioavailability 
 
The common approaches to improve the systemic bioavailability of drugs are to deliver 
them by alternative administration routes such as oral, transdermal, nasal, vaginal or rectal. 
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Among these routes, oral administration is the most convenient way to achieve the desired 
therapeutic effects. 
 
Numerous pharmaceutical scientists have logically focused on oral administration route to 
effectively enhance the bioavailability of the drug substances. The key approaches to 
maximize oral drug absorption are described as follows: 
 
 By using efflux pump inhibitors to improve the efficiency of drug transport; 
 By using permeation enhancers to inhibit drug degradation and improve permeability; 
 Modifying the physicochemical properties of drugs for improving drug solubility, 
stability and dissolution rate; 
 Designing the specialized formulation such as nanoparticles, micro-particles and 
liposomes that improve the drug solubility and protect drugs from harsh environment 
of the gastrointestinal tract; 
 Developing stimuli-responsive systems for controlled drug delivery summarizes the 
various strategies that have been investigated and proposed to improve the oral 
bioavailability of drug substances. 
 
 
 
 
 
 
 
 
 
Figure 3: Strategies to improve the oral bioavailability of drug substances 
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LIPID BASED DRUG DELIVERY SYSTEMS  
 
Drugs which are poorly water solubility are made well suitable for lipid-based 
formulation. Water insoluble and weakly basic drugs require special care in the design and 
development of lipid based formulation. These drugs administered in the solubilized form in 
the lipid vehicle may come out of the formulation due to solubilisation in the gastric fluid and 
may precipitate in the intestinal fluid on gastric emptying. The bioavailability of this system 
would depend on how rapidly the precipitates can be resolubilized by the formulation.  
The percentage of new chemical entities synthesized with low aqueous solubility and high 
therapeutic efficacy is growing, this presents a major challenge for the drug delivery. To 
overcome the above challenge different methods were developed for the enhancement of 
bioavailability. 
Lipid based formulations are more effective delivery system for oral route and improve 
bioavailability because of its proven safety and efficacy. Lipid Formulation Classification 
System was established by Pouton et al., It aims to enable in vivo studies for interpreting and 
for the identification of the most appropriate formulations for specific drugs, their 
physiochemical properties are taken into consideration. 
 
Lipid-drug conjugates 
 
 To overcome the limitation of limited loading capacity for highly potent hydrophilic 
drugs and drug expulsion during storage, lipid-drug conjugates have been made. Lipid-drug 
conjugates nanoparticle are prepared either by formation of a salt with a fatty acid or 
alternatively by covalent linkage (e.g. to ester or ethers).  Further process is perform an aqueous 
surfactant solution to a nanoparticle formulation using high pressure homogenization. The 
lipids that can be used for formulation of lipid–drug conjugates include phospholipids, fatty 
acids such as stearic acid, oleic acid, docosahexaenoic acid, etc. and lipoamino acids. 
 
Solid lipid nanoparticles (SLNs) 
 
Solid lipid nanoparticles (SLNs) are composed of melt-emulsified solid lipids like 
highly purified triglycerides, monoglycerides, hard fats, complex glyceride mixtures as matrix 
materials. As they are derived from biodegradable and compatible lipids, SLN represents a 
comparatively stable system with protective effects against serious drug toxicity and harsh 
external environment in comparison to the conventional nanoparticles. In addition, they also 
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offer the advantages of avoidance of organic solvents in their preparation, controlled release of 
drugs and excellent tolerability.  
Of the available methods for preparation, cold high-pressure homogenisation process, 
hot homogenization of melted lipids at elevated temperatures and microemulsion technology 
are considered as the most feasible methods for large scale production of SLNs. Although solid 
lipid nanoparticles (SLNs) have attracted increasing attention due to its advantages, SLNs have 
several limitations, for example, low loading efficiency for some drugs which owing to the 
densely packed lipid crystal network. Furthermore, SLNs also show considerable expulsion of 
the drug during storage.  
Lipid nanocapsules (LNCs) 
 
Lipid nanocapsules (LNCs) provide a new nanotechnology which contributes to oral 
drug delivery development. LNCs are another kind of lipid nanoparticles, composed of an 
internal liquid or semi-liquid oil core and an external lipid layer solid as a core-shell structure. 
LNCs with the unique properties such as controlled release profiles and high bioavailability, 
represent a promising biocompatible drug delivery platform in nanometer range with narrow 
size distribution. The phase inversion temperature (PIT) method proposed by Shinoda and Saito 
led to lipid nanocapsules preparation with good mono-dispersion. LNCs prepared by PIT 
method is based on three main components: an oil phase, an aqueous phase and a non-ionic 
surfactant.  
Furthermore, the temperature cycling process crossing the phase-inversion zone (PIZ) 
plays another role on LNCs formulation. Increasing the number of cycles promotes LNC 
formation and improves the quality of LNC dispersion. Recently, many lipophilic drugs have 
been developed in LNCs form for instance, ibuprofen loaded LNCs for pain treatment; 
indinavir, an inhibitor of HIV1 protease; various hydrophobic anticancer agents. Consequently, 
LNCs provide an attractive drug delivery approach for highly lipophilicity drug substances that 
are usually unsuitable for oral use. 
Nanosuspensions 
 
Nanosuspensions are nanoscale colloidal dispersion of solid drug particles which are 
stabilized by surfactants, polymers or a combination of both. The key difference from 
conventional suspensions is that the particle size distribution of the solid particles in 
nanosuspensions is usually < 1 µm. Nanosuspensions engineering processes presently used are 
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media milling, high pressure homogenization, microprecipitation-high pressure 
homogenization, emulsion diffusion method and melt emulsification method. Owing to the 
enhanced drug solubility, increased surface-volume ratio of the nanocrystals, and improved 
dissolution rate, oral nanosuspensions have been specifically used. Furthermore, 
nanosuspensions are available in various dosage formats such as tablets, pellets, and capsules 
following different manufacturing techniques. Nevertheless, the major challenges in 
nanosuspensions preparation are maintaining colloidal stability and particle size of the 
nanosuspensions during storage. The appropriate selection of the surfactants and/or steric 
stabilizers and the method of fabrication have been sought to prevent the nanocrystal 
aggregation to achieve the nanosuspensions with long-term storage and physiological stability. 
Liposomes 
 
Liposomes are a form of self-assembled lipid bilayer vesicles which composed of one 
or more aqueous compartments are completely enclosed by hydrophilic and/or hydrophobic 
molecules. Due to the core (aqueous)-shell (lipidic) structure, liposomes are available for 
encapsulating hydrophilic drugs in the aqueous core, hydrophobic agents in the lipidic shell, 
meanwhile, amphiphilic molecules distributed through the hydrophobic-hydrophilic layers. In 
addition, using biologically and natural lipids makes liposomes highly biocompatible and 
suitable for in vivo use. 
Recently, research on liposomes technology has been extensively investigated for the delivery 
of various therapeutic and bioactive agents, decreasing toxicity and increasing their 
accumulation at target sites. Nitesh Kumar et al developed lecithin-based silymarin liposomes. 
The results showed that incorporating phytosomal form of silymarin in liposomes had better in 
vitro and in vivo hepatoprotection and better anti-inflammatory effects in histopathological 
changes. Therefore, liposomes can be used in the oral delivery of lipophilic drugs to increase 
its oral bioavailability. 
 
Liquid crystalline nanoparticles (LCNPs) 
 
Liquid crystalline nanoparticles (LCNPs), which combine the properties of both liquid 
and solid states, are self-assembled from polar amphiphilic lipids in the presence of excess 
water. LCNPs are generally prepared by dispersing the liquid crystalline matrix formed into 
water phase using high-energy fragmentation, such as ultrasonication, microfluidization, or 
homogenization. Normally, LCNPs enhance the oral bioavailability of lipophilic drug by 
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improvement of bioadhesiveness, membrane fusing properties, superior encapsulation, 
solubilization, etc. Ni Zeng et al  developed self-assembled LCNPs consisting of soy 
phosphatidylcholine and glycerol dioleate for oral delivery of paclitaxel. The results of this 
study suggest that LCNPs could be a promising approach for enhancing the oral bioavailability 
of lipophilic drugs and agents. 
Self-Nanoemulsifying drug delivery system (SNEDDS) 
 
Self-nanoemulsifying drug delivery systems (SNEDDS) are isotropic mixtures of oil, 
surfactant, co-surfactant and drug that rapidly form fine oil-in-water (o/w) nanoemulsions 
when introduced into aqueous medium under mild agitation. In the human body, the agitation 
required for formation of nanoemulsions is provided by digestive motility of the 
gastrointestinal tract. In comparison with the ready to use nanoemulsions or nanosuspensions, 
SNEDDS have shown many advantages such as: physical or chemical stability profile 
improvement in long term storage; possibility of filling into soft/hard gelatin capsules, which 
results in attractive commercial viability and patient acceptability; no palatability-related 
issues.In recent years, Self-emulsifying drug delivery systems (SNEDDS) is used to improve 
the oral bioavailability of poorly water-soluble drugs. 
 
Polymer based nanocarriers 
 
Polymeric nanoparticles 
 
Polymeric nanoparticles are submicronic solid particles where drug is encapsulated or 
adsorbed onto particles. With the increasing study on polymers, polymeric nanoparticles have 
emerged as a promising approach in oral drug delivery field due to their unique properties such 
as improved drug stability, the duration of the therapeutic effect and to minimize drug 
degradation and metabolism etc. A variety of biodegradable and biocompatible polymers have 
been used in the research of polymeric nanoparticle preparation include starch, chitosan, 
poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL), 
etc. These polymers can be used either separately or combined with each other. The advantages 
of polymeric nanoparticles can be their high stability in the gastrointestinal tract, protection 
and controlled release of the incorporated drugs, flexibly modulating, and offering targeting 
with improved cellular uptake. However, the potential challenge for polymeric nanoparticles 
is associated with the polymer toxicity and the residues of organic solvents during the 
preparation. In addition, some of the synthetic polymers are highly hydrophobic and not 
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friendly to hydrophilic drugs. These limitations of polymeric nanoparticles should be addressed 
in the future studies. 
Polymeric micelles 
Polymeric micelles are nanosized supramolecular constructs formed by amphiphilic 
molecules consisting of an inner hydrophobic core and an outer hydrophilic entity. As a core-
shell structure, the hydrophobic core acts a reservoir for lipophilic drugs whereas the 
hydrophilic shell protects the drugs to avoid the inactivation and increase the bioavailability 
and retention. 
Two main methods have been commonly used to produce drug-loaded polymeric micelles. 
Direct dissolution involves dissolving both polymer and drug in an aqueous solvent. 
Alternatively, organic solvents are employed when both polymer and drugs are highly 
hydrophobic. As reported by literatures, polymeric micelles are stable in terms of both 
thermodynamic and kinetics, imparting overall structural stability. Moreover, polymeric 
micelles allow a multifunctional design to achieve integrated diagnostic and therapeutic 
functions and molecular targeting capabilities.  Nevertheless, more efforts are still required in 
order to overcome the challenges, for examples, low drug loading, low permeability in 
transport through intestinal membrane. 
Polymer-drug conjugates 
 
By definition, polymer-drug conjugates are formed by the conjugation of a 
biocompatible polymeric carrier and low-molecular weight biologically active molecule(s) 
through a biodegradable linker. One of the major differences between polymer–drug 
conjugates and other nanocarriers that contain physically entrapped drugs is that the drug 
molecules are covalently bound to the polymers. Mostly, the presence of polymers increases 
the solubility of hydrophobic drugs, modifies drug dispersion profile, extends plasma 
circulation half-life, and improves its pharmacokinetic profile, in turn, enhancing the oral 
bioavailability of the drugs. On the other hand, the biodegradable linker can also become active 
by triggering drug release under certain conditions, such as a change in pH or in the presence 
of enzymes, such as esterases, lipases or proteases. A pH-sensitive amphiphilic dendritic 
polyrotaxane drug-polymer conjugate by covalently linked doxorubicin (DOX) and dendritic 
polyrotaxane has been designed and successfully fabricated by Yang Kang et al. This pH-
sensitive drug-polymer conjugate showed a significantly faster drug release at mildly acidic 
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condition while without burst release in aqueous at a physiological pH of 7.4. The results 
proved that this conjugate has tremendous potentials for targeted cancer therapy. 
Drug nanocrystals   
 
Besides liposomes, nanocrystals are the most successful nanocarriers when considering 
the first marketed products as well as the total number of commercial products and in clinical 
phases. Nanocrystals are nanosized crystals of pure drug particles with the surfactants or 
polymeric steric stabiliser absorbed onto the surface of drugs. Thus, drug nanocrystals possess 
a 100% drug loading in contrast to polymer or lipid-based nanoparticles. As we known, 
decrease in particle size provides a greater surface area in the diffusion layer and leads increase 
of the drug dissolution rate, furthermore, enhancing the absorption . Industrially, the drug 
nanocrystals are produced with four main technologies, including top-down (e.g. pearl milling, 
high pressure homogenisation), bottom-up (e.g. precipitation) and combination (sonication–
precipitation) and chemical approaches. 
Dendrimers 
 
Dendrimers are the new artificial well-defined polymeric nanostructures exhibiting 
tree-like architecture that consist of a hydrophobic central core, branching units and terminal 
functional groups. Dendrimers possess definite molecular weight, shape, size and specific 
physicochemical properties including host–guest entrapment properties. Unlike many 
traditional polymeric nanocarriers, dendrimers can be manufactured in almost any size whereas 
the diameters are commonly 10-20 nm. In addition, dendrimers also have a narrow 
polydispersity and well defined spherical shape with a variety of terminal functional groups. 
These unique structural nanosized macromolecules offer multiple ways for incorporation of 
plenty of drugs which pose oral delivery challenges. 
First, drug molecules can be physically encapsulated in the core of the dendrimers. 
Second, drug molecules can be chemically conjugated to the functional end groups on the 
dendrimer surface during or after synthesis. Third, dendrimer drug networks can be formed. 
As an approach for the oral bioavailability enhancement, dendrimers provide many potential 
mechanisms. First, the dendrimers entrap the drugs to prevent the drug degradation from harsh 
gastrointestinal tract. Next, dendrimers may act as permeability enhancers and alter the barrier 
of the intestinal epithelium, thereby improve the drug absorption. Last, the dendrimer-drug 
conjugate may be transported across the intestinal epithelium by itself. The properties of 
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dendrimers such as size, surface charge and conformation significantly affect the drug delivery 
and absorption in the GIT. Moreover, larger dendrimers have been found be more toxic, in 
comparison with the smaller ones. Conclusively, dendrimers are promising delivery system, 
but more efforts should be required to overcome challenging biological barriers. 
Others 
  
Except the above mentioned strategies, many other nanotechnologies are also employed 
in the oral drug delivery, for example, carbon nanotubes, silica and silicon nanoparticles, 
nanogels and so on. Carbon nanotubes possess unique hollow cylindrical structures, high 
surface area, conductivity, optical and potential higher absorption capabilities, allow the 
incorporation of drug molecules for controlled and site-specific delivery. Silica/silicon 
nanoparticles offer a high absorption capacity, mesoporous channel to change the crystalline 
state of the drugs and the possibility to tailor the physicochemical properties. The 
biocompatibility, chemical properties and mesoporous structure make silica/silicon 
nanoparticles an excellent alternative for drug delivery application. Nanogels are commonly 
used for oral controlled drug delivery with the advantages such as thermodynamic 
compatibility with water, enviro-intelligent, stimuli-sensitive and sustained release. 
In recent years, SNEDDS have attracted more and more attention as the mean to 
enhance the oral bioavailability of poorly soluble and highly metabolized drugs. Nevertheless, 
conventional SNEDDS also require a relatively large amount of surfactants, which may induce 
GI irritation and side-effects. In order to achieve a safe and efficient delivery system for the 
poor oral bioavailability drugs, we have designed a novel self-nanoemulsifying drug delivery 
system with high proportion lemon essential oil as carrier for lipophilic drugs. 
 
Self-emulsifying drug delivery systems (SEDDS) 
 
Self-emulsifying drug delivery systems (SEDDS) are emulsion pre-concentrates or 
anhydrous forms of emulsion. These systems (SEDDS) are ideally isotropic mixtures of drugs, 
oils and surfactants, sometimes containing co-surfactant or co-solvents. Upon mild agitation 
followed by dilution with aqueous media, SEDDS can form fine oil-in-water emulsions 
spontaneously. In gastrointestinal tract of human body, the agitation required for formation of 
emulsions is provided by gastric mobility, the aqueous media are gastrointestinal fluids. In 
comparison with ready-to-use emulsions, which are metastable dispersed forms, SEDDS 
possess improved physical and/or chemical stability profile upon long-term storage, and also 
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easy manufacture property. Thus, for the lipophilic drugs that exhibit poor water solubility and 
rate−limited dissolution, SEDDS may offer an improvement in the rate and extent of absorption 
and result in more reproducible blood−time profiles. 
Types of SEDDS 
SEDDS include both self-microemulsifying drug delivery systems (SMEDDS) and 
self-nanoemulsifying drug delivery systems (SNEDDS).  
 
 
 
 
 
 
 
  
 
Figure 4: Types of Self emulsifying drug delivery system 
 
SMEDDS indicate the formulations producing transparent microemulsions with 
droplets size range between 100 and 250 nm while SNEDDS form emulsions with the globule 
size range lower than 100 nm. The term ‘droplet’ is used to describe micelles, mixed micelles 
which exist in the emulsions. In details, the microemulsion is a thermodynamically stable 
colloidal dispersion consisting of small spheroid particles (comprised of oil, surfactant, and 
possibly co-surfactant) dispersed within an aqueous medium and thus in equilibrium. In 
contrast, the nanoemulsion is non-equilibrium colloidal dispersion system that over time 
spontaneously will exhibit coalescence of the dispersed droplets. 
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 However, nanoemulsions can have a relatively high kinetic stability, and in this case it 
will be difficult to distinguish on the previous basis micro and nano-emulsions. Actually, the 
structure of the droplet in both nanoemulsion and microemulsion are very similar: the non-
polar tails of surfactant molecules protrude into the lipophilic core formed by the oil, while the 
polar head groups protrude into the surrounding aqueous phase  
Nanoemulsions 
 
Nano-emulsions are a new class of emulsion which can be defined as an emulsion with uniform 
and extremely small droplet sizes, typically in the range of 20–200 nm. The physical 
appearance of nano-emulsion is transparent or translucent because of their small droplets size. 
Their small droplets size makes it kinetically stable against sedimentation or creaming for a 
long period of time. The use of nano-emulsions in oral dosage forms, achieve promising results 
in increasing the effectiveness of the drug at the target site, as well as can increase drug 
bioavailability, enhanced permeability and therapeutic functions. Efforts are madewith 
SNEDDS to enhance the oral bioavailability of lipophilic drugs in order to increase their 
pharmacological efficacy. 
Nanoemulsions are non-equilibrium, heterogeneous systems composed of oil droplets 
dispersed in an aqueous medium and stabilized by surfactant molecules. In a nanoemulsion, 
the oil droplets serve as the reservoir for hydrophobic drugs. Moreover, nanoemulsions are 
regarded as kinetically stable, isotropic and transparent without any apparent coalescence 
during the long time storage. 
The nanoemulsions are usually stabilized by large amount of surfactants, which can 
improve drug solubilisation, protect active compound against physicochemical and enzymatic 
degradation and modify the permeability of the GIT membrane. Non-ionic surfactants are 
commonly preferred due to their less toxicity, less affected by pH and ions than ionic and 
amphiphilic surfactants, and better compatibility with biological systems. Combinations of 
different surfactants have also been employed to decrease the droplet size and improve the 
stability of nanoemulsions. Methods used for the production of nanoemulsions include high-
pressure homogenization, microfluidization, ultrasonication, spontaneous emulsification and 
so on. The advantages of nanoemulsions are increased drug loading, tissue targeting and 
enhanced permeability. 
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SELF NANO EMULSIFIED DELIVERY SYSTEMS 
Lipid based formulations such as self nano emulsified delivery systems (SNEDDS) are 
said to increase the absorption of the lipophilic drugs. SNEDDS are isotropic mixtures of oil, 
surfactant, co-surfactant and drug that form oil in water emulsion in aqueous environment 
under gentle agitation. This forms a good mode for delivering poorly soluble drugs orally by 
increasing their bioavailability and stability. They offer large interfacial area between the oil 
and GIT fluids and enhance the rate of absorption of the drugs 
 
Self-nanoemulsifying Drug Delivery system  (SNEDDS) is isotropic mixture of natural 
or synthetic oil, surfactants and co-surfactants that havea unique ability of forming fine oil-in-
water (O/W) nano-emulsions under mild Agitation followedaqueous media. Self-Nano 
emulsifying Drug Delivery System having size range of globules is less than 100nm under 
dispersion of water. 
 
 
Figure 5: Self Emulsifing drug delivery system 
 
SNEDDS spread readily in the gastrointestinal tract, and the digestive motility of the 
stomach and the intestine provide the agitation necessary for self-emulsification. Spontaneous 
emulsification to produce fine oil-in-water emulsion under gentle agitation followed by 
dilution in aqueous media can occur in oil and surfactants mixture. The production of self-
emulsifying formulation involves several combinations of oil and surfactants, also the 
efficiency of self-emulsifying formulation can be influenced by several factors such as HLB 
value of the surfactant and surfactant concentration. The components used must be suitable for 
oral ingestion, such as medium chain triglyceride oils and nonionic surfactants. 
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These SNEDDS are given in the form of soft or hard gelatin capsules or in the form of 
Tablets. They reach the gastro intestinal tract and the GI motility of the stomach provides the 
agitation for self-emulsification. Because of this self-emulsification the drug is given as small 
droplets with size less than 5μm for improved solubility. After administering orally, lingual 
and pancreatic lipases act on the oily phase of the SNEDDS that result in the formation of 
emulsified mono-glycerides, di-glycerides and fatty acids. This in the presence of bile acids 
leads to the formation of intestinal mixed micelles. When these mixed micelles pass through 
the enterocytes, it leads to the formation of chylomicrons. These drain the drug into the 
lymphatic vessels and not in the blood vessels thus bypassing the first pass effect. Thus the oral 
bioavailability gets increased.  
 
These study shows preparation of various kind of SNEDDS formulation by performing trial 
batches of various oils (sunflower oil, soyabean oil, olive oil), surfactants (Acrysol derivatives 
and other Gattefosse surfactants, Tween 80, Tween 20), cosurfactants (captex 200,captex 
300,labrafil M 2125) and cosolvents (PEG 400,Propylene Glycol, ethanol) with drug to assess 
the ability of drug in solubilized form and to form a transparent solution for better 
emulsification ratio of Surfactant: Cosurfactant: Cosolvents remains same. Nonionic 
surfactants with high HLB (HLB = 10) and subsequent hydrophilicity is necessary for the 
instant creation of oil in water droplets and/or rapid spreading of the formulation in the aqueous 
environment providing a good dispersing/self-emulsifying performance. The surfactants are 
amphiphilic in nature have ability to dissolve and solubilize to some extent high quantities of 
the hydrophobic drug. In SNEDDS generally surfactant of HLB value 8-16 is used. 
 
Self nanoemulsifying drug delivery system (SNEDDS) has received particular attention as a 
means of improvement of oral bioavailability poorly soluble and absorbed drugs. SEDDS are 
the mixture of oils, surfactants, and co-surfactants. This becomes emulsify when come in 
contact with aqueous solution of GIT under the condition of gentle stirring and digestive 
motility. SNEDDS includes various dosage forms like capsule, tablets, beads, microspheres, 
nanospheres, etc. thus SNEDDS could efficiently improve oral absorption of the sparingly 
soluble drugs by self-emulsification. For the improvement of bio-availability of drugs with 
such properties presents one of the greatest challenges in drug formulations. 
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   Figure 6: Preparation of SNEDDS 
 
The bioavailability enhancing property has been associated with a number of in-vivo properties 
of lipidic formulation including:  
 The formation of fine dispersions and micellar suspensions to prevent precipitation and 
recrystallization of the drug compound.  
 The ability of certain lipid compounds and their metabolites to initiate changes in the 
gastrointestinal fluid to favor improved drug absorption.  
 The inhibition of cellular efflux mechanisms and pre-absorptive metabolism by gut 
membrane-bound cytochrome enzymes, further augmenting the absorption enhancing 
properties of these formulations.  
 Certain lipidic excipients are associated with selective drug uptake into the lymphatic 
transport system, thereby reducing the effect of first-pass drug metabolism in the liver.  
 
SNEDDS are particularly useful when the poorly water soluble compounds are to be pre-
dissolved in a suitable solvent and filled into capsules. The main benefit of this approach is that 
pre-dissolving the compound overcomes the initial rate limiting step of particulate dissolution 
in the aqueous environment within the GI tract. However, a potential problem with this system 
is that the drug may precipitate out of solution when the formulation disperses in the GI tract, 
particularly if a hydrophilic solvent is used (e.g. polyethylene glycol). But alternatively, if the 
drug can be dissolved in a lipid vehicle there is less potential for precipitation on dilution in 
the GI tract, as partitioning kinetics will favor the drug remaining in the lipid droplets. 
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Some of the potential advantages of self-emulsifying lipid formulations include 
physicochemical stability, enhanced oral bioavailability enabling reduction in dose, consistent 
temporal profiles of drug absorption, selective targeting of drug towards specific absorption 
window in GIT, control of drug delivery profiles, ability to increase Cmax, AUC, and reduced 
tmax, linear AUC-dose relationship, reduced variability including effect of food, protection of 
sensitive drug substances, high drug payloads and flexibility of designing liquid or solid dosage 
forms. 
 
Advantage of SNEDDS  
1. Enhanced oral bioavailability enabling reduction in dose.  
2. Selective targeting of drugs toward specific absorption window in GIT.  
3. High drug payloads.  
4. Control of delivery profiles.  
5. Emulsion is sensitive and metastable dispersed forms while S(M)EDDS are physically stable  
    formulation that are easy to manufacture.  
6. As compared with oily solutions, they provide a large interfacial area for partitioning of the  
    drug between oil and water. 
7. SEDDS help to wide distribution of the drug throughout the stomach and promote wide  
distribution of the drug throughout the GI tract, thereby minimizing the irritation frequently 
encountered during extended contact between bulk drug substance and the gut wall.  
Potential advantages of these systems include enhanced oral bioavailability, more consistent 
temporal profiles of drug absorption, selective drug targeting toward a specific absorption 
window in the GI tract, and drug protection from the hostile environment in the gut. Thus 
for lipophillic drug compounds that exhibit dissolution rate limited absorption, these system 
may offer an improvement in the rate and extent of absorption. 
 
Disadvantages of SNEDDS 
1. Traditional dissolution methods do not work, because these formulations potencially are 
dependent on digestion prior to release of the drug. 
2. This in vitro models needs further development and validation before its strength can be 
evaluated.  
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Further development will be based on in vitro - in vivo correlations and therefore different 
prototype lipid based formulations needs to be developed and tested in vivo in a suitable 
animal model. 
The drawbacks of this system include chemical instabilities of drugs and high surfactant 
concentrations in formulations (approximately 30-60%) which GIT. 
Limitation of SNEDDS  
conventional SEDDS, which are mostly prepared in a liquid form and orally administered in 
soft or hard gelatin capsules, can make some disadvantages such as high production costs, low 
drug incompatibility and stability, drugs leakage and precipitation, capsule ageing. Then 
incorporation of liquid SEDDS into a solid dosage form is compelling and desirable. Recentl  
y, a new drug delivery technology-solid SEDDS (S-SEDDS) which combine the advantages of 
SEDDS and those of solid dosage forms, have been investigated. 
 
Factors affecting SNEDDS 
Drugs which are administered at very high dose are notsuitable for SNEDDS, unless they 
exhibit extremely good solubility in at least one of the components of SNEDDS, preferably 
lipophillic phase. The drugs exhibit limited solubility in water and lipids are most difficult to 
deliver by SNEDDS. 
 
The ability of SNEDDS to maintain the drug in solubilized form is greatly influenced by the 
solubility of the drug in oily phase. If the surfactant or co-surfactant is contributing to a greater 
extent for drug solubilization, then there could be a risk of precipitation, as dilution of 
SNEDDS will lead to lowering of solvent capacity of surfactant or co-surfactant. 
 
Components of SNEDDS  
It is very important to select and optimize the quantities of the SNEDDS components. Because 
the components of SNEDDS and their concentrations will influence the various characteristics 
of nano emulsions, such as droplet size, polydispersity index, self-nano emulsification time and 
in vitro drug release. In general, the selection of the components based on their ability to 
solubilize the drug of interest and also on their ability to form spontaneous 
emulsions/nanoemulsions. The various components of SNEDDS used in the table no. 
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Oils: Long and medium-chain triglyceride oils with different degrees of saturation have been 
used for the design of SEDDS. Oil can facilitate self-emulsification and increase the fraction 
of lipophilic drug transportation via the intestinal lymphatic system, thereby increasing 
absorption from the GI tract. Modified or hydrolyzed vegetable oils have contributed widely 
to the success of SEDDSs owing to their formulation and physiological advantages. Novel 
semi-synthetic medium-chain triglyceride oils have surfactant properties and are widely 
replacing the regular medium- chain 12-14 triglyceride.  
 
Surfactant: Non-ionic surfactants are used in formulation of SNEDDSs. The usual surfactant 
concentration is between the ranges of 30–60% w/w of the formulation in order to form a stable 
SNEDDS. Surfactant having a high hydrophilic lipophilic balance (HLB) and hydrophilicity 
assists the immediate formation of o/w droplets and/or rapid spreading of the formulation in 
the aqueous media. Surfactants are amphiphilic in nature and they can dissolve or solubilize 
relatively high amounts of hydrophobic drug compounds. This can prevent precipitation of the 
drug within the GI lumen.  
 
Co-solvents: Co-solvents used in SEDDS helps to dissolve large amounts of hydrophilic 
surfactants or the hydrophobic drug in the lipid base. 
 
 
 
 
    Table 1: Components of SNEDDS 
Component Examples  
   
 Fatty acids Palmitic acid, Stearic acid, Oleic acid 
 Fatty acid esters Glyceryl monooleate [Capmul1 GMO,Imwitor1 
  948, Peceol1], Glyceryl monostearate [Capmul1 
  GMS-50, Imwitor1 191], Glyceryl monolinoleate 
  [MaisineTM 35-1], Glyceryl palmito stearate 
  [Precirol1 ATO 5], Glyceryl behenate [Compritol1 
  888 ATO] , Ascorbyl palmitate, Medium chain 
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  mono- and diglycerides [Capmul1 MCM], Medium 
  chain triglycerides [Labrafac1 CC Miglyol1 810 
  and 812], Glyceryl dilaurate, Propyleneglycol 
  monolaurate [Lauroglycol1 FCC, Capmul1 PG-12] 
 Propyleneglycol esters Propyleneglycol monolcaprylate [Capryol1 90, 
  Capmul1 PG-8], Propylene glycol dicaprylocaprate 
  [Labrafac1 PG] 
Lipids and oils 
 
Miscellaneous Stearyl alcohol,Phospholipids, Bees Wax,Vitamin E 
Surfactants/ stabilizers   Caprylocaproyl polyoxyl-8-glycerides [Labrasol1], 
Polyoxyethylene sorbitan fatty acid esters   
  [Tween1], Polyoxyethylene castor oil derivatives 
   
   [Cremophor1, Lipocol1], Polyvinyl alcohol, 
  Sorbitan esters [Span1], Tocopherol polyethylene 
  glycol, succinate (TPGS)Macrogol fatty acid 
  glycerides [Gelucire1 44/ 14, Gelucire1 50/13], 
 Co-surfactants Hydroxyl propyl methyl cellulose, Poloxamer, 
  
Phospholipids and PEGylated phospholipids, 
 
 co-solubilizers Polyvinyl pyrrolidone, Bile acids (sodium 
  deoxycholate), Cellulose derivatives, Polyglyceryl- 
 
 
co-stabilizers 
3 dioleate [Plurol1, Oleique1 CC497] 
 
  
Propylene glycol, Glycofurol, Phospholipids, 
Oleoyl/ 
linoleoyl polyoxyl-6-glycerides [Labrafil1], 
Polyethylene glycol, Triacetin, Ethanol, Diethylene 
glycol monoethyl ether [Transcutol1 HP] 
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Telmisartan 
Telmisartan is Angiotensin II Receptor Antagonist, which is used in the prevention and 
treatment of Hypertension.Telmisartan belongs to class II drug in BCS classification i.e. low 
solubility and high permeability.One of the major problems with this drug is its low solubility 
in biological fluids, which results into poor bioavailability after oral administration.The 
solubility of Telmisartan in aqueous medium was very low i.e. 0.078 mg/ml in water. Absolute 
bioavailability  of the Telmisartan was 42-58% and biological half-life is only 24 hours that 
results into poor bioavailability after oral administration.  
 
 
 
Figure 7: Mechanism of action of  Telmisartan 
 
Poor solubility of Telmisartan leads to poor dissolution and hence variation in bioavailability. 
Thus increasing aqueous solubility and dissolution of Telmisartan is of therapeutic importance. 
A many number of approaches have been developed to improve the drug solubility and 
dissolution of drugs. The solid dispersion is a technique to achieve this goal particularly the 
poor aqueous soluble drugs in which the drug is incorporated in to water soluble polymeric 
matrix . In this research the solubility and bioavailability of telmisartan in conjugation with 
various carriers by using various methods were studied.besides this solubility and dissolution 
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study, the various evaluation methods were carried out to determine the physico chemical 
properties of physical mixture and solid dispersions in comparison to pure drug.  
 
Previous researchers have made attempts to improve the aqueous solubility of telmisartan by 
preparing solid dispersion and solid lipid nanoparticles. The preparation of solid dispersion is 
easy, but its limitations include stability of the drug and the difficulty of incorporating into 
solid dispersion in suitable dosage forms. For solid dispersion, the amount of carriers used is 
often large, and thus if the dose of the active ingredient is high, the tablets or capsules formed 
will be large in volume and difficult to swallow.  
 
Moreover, the carriers used are usually expensive and the freeze-drying or spray-drying method 
requires particular facilities and processes, leading to a high production cost. Though a 
traditional solvent method can be adopted instead, it is difficult to deal with co-precipitates 
with a high viscosity. One potential problem with solid lipid nanoparticles formulation is that 
the drug may favor a more thermodynamically stable state, which can result in the compound 
crystallizing in the polymer matrix.  
 
There is a necessity to develop a formulation that would offer rapid dissolution of temisartan 
and improve its bioavailability and finally therapeutic efficacy. Lipid-based formulation 
approaches, predominantly the self-emulsifying drug delivery system (SEDDS), illustrate their 
potential as alternative approaches for the delivery of hydrophobic drugs. Dosing of drug 
substances that exhibit poor water solubility, but sufficient lipophilic properties in a 
predissolved state are advantageous in view of the fact that the energy input allied with a solid-
liquid phase transition is circumvented, thus overcoming the slow dissolution process after oral 
intake. 
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LITERATURE REVIEW 
 Hyma .P1, Anusha Chandra, Abbulu K et al., (2014) Telmisartan SMEDDS were 
prepared as a novel technique to improve the solubility of poorly soluble drug. The 
preformulation studies done clearly indicate good compatibility of the drug with the 
various excipients used. The reduction of particle size was clearly depicted in the 
droplet size measurements where the size is reduced to nanometer range, which has led 
to increase in dissolution rates as shown in the dissolution studies and graph.. Thus it 
can be concluded that micro emulsion formulation can be used as a successful tool to 
enhance the bioavailability of the drug, and there formulations can be further tested in 
vivo by using animal models. 
 
 Mr. Girish C. Soni, S.K. Prajapati, Nirvesh Chaudhri et al.,(2014) Ease of 
manufacture and scale-up is one of the most important advantages that make SNEDDS 
unique when compared with other novel drug delivery systems, such as solid 
dispersions, liposomes and nanoparticles. SNEDDS require very simple and 
economical manufacturing facilities, such as simple mixer with an agitator and 
volumetric liquid filling equipment for large-scale manufacturing. These SNEDDS are 
better formulation for drugs with poor solubility. This gives good absorption profiles 
thus offering high bioavailability for such drugs when administered orally. However 
the role of nanoscale in improving the transport of drug across biological membranes 
and therapeutic efficacy is debatable in the case of nanoemulsions. The amenability of 
converting SNEDDS into solid self-nanoemulsifying systems enables development into 
solid dosage form. Thus, the solid self-nanoemulsifying system can serve as platform 
technology for delivering poorly soluble drugs. Although a lot of research is being 
carried out in this area, other aspects, such as in vito /in vivo correlation, need to be 
established 
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 Parul Jaiswal, Geeta Aggarwal, Sasidharan Leelakumari Harikumar, and 
Kashmir Singh et al., (2014) Self-microemulsifying drug delivery system is a vital 
tool in overcoming the formulation difficulties and improving the oral bioavailability 
of hydrophobic/lipophilic drugs. In this study, SMEDDS and solid-SMEDDS 
formulations of poorly water-soluble drug, telmisartan were successfully prepared by 
the ultrasonication method and adsorbent technique respectively for oral 
administration. Further, they were assessed for in vitro performances. Among various 
formulations, F3 in SMEDDS and SF3 in solid-SMEDDS showed promising results in 
the terms of globule size analysis, self-emulsification time, zeta potential, drug loading 
efficiency and in vitro drug release. It could be summarized that SMEDDS formed from 
castor oil, tween 20 and propylene glycol as oil, surfactant and co-surfactant is a 
promising approach to improve the solubility, dissolution rate and hence bioavailability 
of telmisartan. The optimized formulations showed significantly improved drug release 
as compared to pure drug. Solid-SMEDDS were preferred over SMEDDS in terms of 
stable dosage form. It can be concluded that telmisartan solid-SMEDDS offer more 
predictable and more extensive drug release/absorption than the corresponding 
conventional formulations. The results from the study showed the utility of solid-
SMEDDS to enhance solubility and bioavailability of sparingly soluble compounds like 
telmisartan, which can be helpful to reduce dose and related side effects of the drug. 
The present exploratory work successfully illustrates the potential utility of solid-
SMEDDS for the delivery of poor water-soluble compounds. 
 
 Sindhu Raavi*, Subramanian S, Surya Kiran Vuddisa et al., (2014) It can be 
concluded from the experimental study carried out that the formulation of a poorly 
water soluble drug, Atorvastatin calcium , into a Supersaturated Self Nanoemulsifying 
Drug Delivery System yields a formulation with the droplets in the nano size range with 
good zeta potential. The in vitro study of the best formulation AS- 3s SNE tablet with 
2% starch as binder showed a 2.5 fold increase in the bioavailability when compared to 
the marketed formulation. 
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 Ali M. Nasr *, Ahmed R. Gardouh , Hassan M. Ghonaim and Mamdouh M. 
Ghorab et al., (2016) In this study, a novel liquid SNEDDS consisting of Capryol 90, 
Cremophor RH40 and Transcutol HP as an oil phase, surfactant and co-surfactant, 
respectively, was formulated and further developed into a solid SNEDDS by a spray-
drying technique using Aerosil 200 as the solid carrier. From this study it was concluded 
that the prepared liquid SNEDDS was thermodynamically stable with good self 
emulsification efficiency and having globule size in nanometric range which may be 
physiologically stable. Study also concluded that S-SNEDDS of IRB prepared by a 
spray-drying technique using Aerosil 200 as the solid carrier have good flow properties 
and drug content. This solid SNEDDS preserved the self-emulsification performance 
of the liquid SNEDDS and gave a faster in-vitro dissolution rate than the crude powder 
and marketed product. Results of SEM demonstrate that spherical particles of S-
SNEDDS can be obtained without agglomeration. Considering the limitations 
associated with liquid SNEDDS, a solid powder formulation should be a more 
acceptable form. Furthermore, our results suggest that the S-SNEDDS could be 
considered and further evaluated for the oral delivery of lipophilic poorly soluble drugs 
for which an oral route of administration is desirable. In conclusion, Self emulsifying 
drug delivery systems were a promising approach for the formulation of IRB. S-
SNEDDS appeared to be an interesting approach to improve problems associated with 
oral delivery of IRB. Thus S-SNEDDS can be considered as novel and commercially 
feasible alternative to current marketed IRB. Finally, the oral delivery of hydrophobic 
drugs can be made possible by SSNEDDS, which have been shown to substantially 
improve the oral bioavailability 
 
 
 NiraliPadia, Arunkumar Shukla, PragnaShelat et al .,(2015) In this study, 
SMEDDS     of     Telmisartan were prepared and evaluated for their in vitro and in vivo 
behavior. Prepared liquid SMEDDS was thermodynamically stable with good self 
emulsification efficiency and having globule size in nanometric range which may be 
physiologically stable. The optimized formulation consisting of Telmisartan (20mg), 
Capmul MCM (14.40%w/w), Tween 80 (27.20% w/w) and Propylene glycol (54.40% 
w/w) exhibited faster release profiles with a rapid rate of emulsification. The optimized 
SMEDDS formulation of Telmisartan showed a significant increase in oral absorption 
compared to the marketed product. The exposure (Cmax and AUClast) of developed 
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SMEDDS was found to be comparatively higher (1.54 fold) than reference marketed 
product indicating better rate and extent of absorption than reference formulation. Thus, 
SMEDDS can be regarded as a novel and commercially feasible alternative to current 
Telmisartan formulations. However, further studies in the higher animals and human 
beings need to be performed before this formulation can be commercially exploited.  
 
  Rahul S. Narkhede, Kishor N. Gujar, Vaishali M. Gambhire* et al ., (2013) The     
present study has clearly showed the potential utilization of S-SNEDDS for formulating 
NEB with improved aqueous solubility, stability and in-vitro drug release. The S-
SNEDDS with relatively high cryoprotectant effect was prepared which self-emulsified 
easily with mean emulsion droplet size of 156.34 nm. Stability study and cloud point 
study confirmed that the S-SNEDDS had no dilution effect and was stable at 0.1 N HCl 
and phosphate buffer 6.8 without any change in emulsion droplet size. 
 
 Ali Nasr*, Ahmed Gardouh , and Mamdouh Ghorab , et al ., (2016) In this study, 
liquid SNEDDS was formulated and further developed into solid SNEDDS by a spray-
drying technique using Aerosil 200 as the solid carrier. From this study, it was 
concluded that the prepared liquid SNEDDS was thermodynamically stable with good 
self-emulsification efficiency and having globule size in the nanometric range which 
may be physiologically stable. It was also concluded that S-SNEDDS preserved the 
self-emulsification performance of the liquid SNEDDS and gave a faster in vitro 
dissolution rate than the crude powder and marketed product. Furthermore, our results 
suggest that S-SNEDDS could be considered and further evaluated for the oral delivery 
of lipophilic poor soluble drugs for which an oral route of administration is desirable. 
In conclusion, self-emulsifying drug delivery systems represented a promising 
approach for the formulation of OLM. S-SNEDDS appeared to be an interesting 
approach to improving problems associated with oral delivery of OLM. Thus, S-
SNEDDS can be considered as a new and commercially feasible alternative to current 
marketed OLM. Finally, the oral delivery of hydrophobic drugs can be made possible 
by S-SNEDDS, which have been shown to substantially improve the oral 
bioavailability. 
 
 
 
 Literature Review 
 
Department of Pharmaceutics, PSG College of Pharmacy Page 27 
 
 Payal Gupta, Pramod Kumar Sharma, Nitin Kumar, Yogesh Pawar, Jitendra 
Gupta et al., (2014) SNEDDS is a promising approach for BCS class II or IV and drug 
compounds with poor aqueous solubility. The method used for lipophilic drugs where 
resulting emulsification gives faster dissolution rates. The oral delivery of hydrophobic 
drugs can be made possible by SNEDDS which have been shown to substantially 
improve oral bioavailability with future development of this technology. SNEDDS will 
continue to enable novel applications in drug delivery and solve problems associated 
with the delivery of poorly soluble drugs. 
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                                                             OBJECTIVE  
 
 To prepare SNEDDS of Telmisartan  
 To convert Liquid SNEDDS to Solid – SNEDDS form  
 To characterize the prepared SNEDDS for the size, self emulsification time, drug 
content  
 To improve the in vitro dissolution rate of the solid SNEDDS  
 
 
 
 
 
 
 
 
 
 
 
 
  Plan of work 
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     PLAN OF WORK 
PHASE – I 
 Drug profile   
 Polymer and excipient profile  
PHASE- II 
 Preformulation studies 
a. Identification of drug 
1. Melting point determination 
2. Infrared studies 
b. Solubility studies 
c. Calibration curve 
PHASE - III 
 Preparation of liquid SNEDDS 
 Conversion of liquid SNEDDS to solid SNEDDS 
PHASE- IV  
Characterization of nano particle formulation  
 Particle size determination  
 Zeta potential 
 SEM analysis  
 Self-emulsification time  
PHASE- V 
 In vitro release study 
 
 
  Drug Profile  
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DRUG PROFILE OF TELMISARTAN 
 
 
Telmisartan is in the drug class of angiotensin receptor blockers (ARBs) and is prescribed for the 
treatment of high blood pressure, reducing the risk of heart attack, stroke, or death from 
cardiovascular causes, 
 
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of 
hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the 
angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of 
angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood 
pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties 
that could potentially confer beneficial metabolic effects 
 
 
 Structure  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Structure of Telmisartan.  
 
 
  Drug Profile  
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Chemical Name:- 
 
[4-[[4-methyl-6-(1-methylbenzimidazol-2-yl)-2-propylbenzimidazol-1-yl]methyl] 1,1 ‘ biphenyl] 
 
– 2 carboxylic acid.  
Molecular Formula:- C33H30N4O2 
 
Molecular Weight:- 514.61 
 
Description:- White to off-white crystalline powder. 
 
Melting range:- Between 265.0oC and 272.0oC 
 
Solubility:- Practically insoluble in water, slightly soluble in methanol, sparingly soluble in 
 
methylene chloride, it dissolves in 1M sodium hydroxide. 
 
Partial coefficient:- The Octanol/buffer partial coefficient (log P) for Telmisartan is 
approximately 3.20 
 
Storage & Stability:- Stored in well-closed, light-resistant containers at 5-30°C. When stored 
under these conditions, Telmisartan generally is stable for 24 months after the date of manufacture. 
Indication:- For the treatment of hypertension 
 
Clinical Pharmacology:-  
Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor 
subtype. New studies suggest that telmisartan may also have PPARã agonistic properties that could 
potentially confer beneficial metabolic effects. This observation is currently being explored in 
clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-
converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-
angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release 
of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by 
blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II. 
 
Mechanism of Action:-  
Telmisartan interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by 
binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal 
gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of 
aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Telmisartan 
does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels.
  Drug Profile  
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Pharmacokinetic properties; 
Absorption 
 
Absorption of telmisartan is rapid although the amount absorbed varies. The mean absolute 
bioavailability for telmisartan is about 50 %. When telmisartan is taken with food, the reduction 
in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from 
approximately 6 % (40 mg dose) to approximately 19 % (160 mg dose). By 3 hours after 
administration, plasma concentrations are similar whether telmisartan is taken fasting or with food. 
 
Linearity/non-linearity 
 
The small reduction in AUC is not expected to cause a reduction in the therapeutic efficacy. There 
is no linear relationship between doses and plasma levels. Cmax and to a lesser extent AUC increase 
disproportionately at doses above 40 mg. 
 
Distribution 
 
Telmisartan is largely bound to plasma protein (>99.5 %), mainly albumin and alpha-1 acid 
glycoprotein. The mean steady state apparent volume of distribution (Vdss) is approximately 500 
 
Biotransformation 
 
Telmisartan is metabolised by conjugation to the glucuronide of the parent compound. No 
pharmacological activity has been shown for the conjugate. 
 
Elimination 
 
Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal eliminate 
ion half-life of >20 hours. The maximum plasma concentration (Cmax) and, to a smaller extent, the 
area under the plasma concentration-time curve (AUC), increase disproportionately with dose. 
There is no evidence of clinically relevant accumulation of telmisartan taken at the recommended 
dose. Plasma concentrations were higher in females than in males, without relevant influence on 
efficacy. 
 
After oral (and intravenous) administration, telmisartan is nearly exclusively excreted with the 
faeces, mainly as unchanged compound. Cumulative urinary excretion is <1 % of dose. Total 
plasma clearance (Cltot) is high (approximately 1,000 ml/min) compared with hepatic blood flow 
(about 1,500 ml/min).  
 
 
 
 
 
 
   
  
  Excipients profile 
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  EXCIPIENTS PROFILE 
POLYETHYLENE GLYCOL  
Synonyms : Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; 
  PEG;Pluriol E; polyoxyethylene glycol. 
Chemical Name : a-Hydro-o-hydroxypoly(oxy-1,2-ethanediyl) 
Empirical Formula : HOCH2 (CH2OCH2) mCH2OH where m represents the 
  Average number of oxyethylene groups. 
Structural Formula:    
 
 
 
 
 
 
 
 
 
Molecular Weight : 3000 to 4800 g/mol 
Functional Category : Ointment base; plasticizer; solvent; suppository base; tablet 
  and capsule lubricant 
Description : The USP32–NF27 describes polyethylene glycol as 
  being an addition polymer of ethylene oxide and water. 
  Polyethylene glycolgrades 200–600 are liquids; grades 1000 
  And above are solids atambient temperatures. Liquid grades 
  (PEG 200–600) occur as clear, colourless or slightlyyellow- 
  colored, viscous liquids. They have a slight but characteristic 
  odour and a bitter, slightly burning taste 
   
  
  Excipients profile 
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CINNAMON OIL 
 
 
 
Synonyms 
 
 
 
Description 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Composistion 
 
 
 
: Cassia oil,cinnamon bark oil,cinnamomum zeylanicum,bloom 
 
bark oil 
 
: Cinnamon bark oil posses the delicate aroma of the spice and a 
 
sweet pungent taste. Its major constituent is cinnamaldehyde but 
 
other minor components impart the characteristic odour and 
 
flavour. It is employed mainly in the flavouring industry where it 
 
is used in meat and fast food seasoning ,sauces,pickles,baked 
 
goods,cola type drinks,confectionary and in dental and 
 
pharmaceutical preparations. Perfumery applications are far 
 
fewer than in flavours because the oil has some skin sensitising 
 
properties ,but is can be used limitedly in a few perfumes. 
 
: The primary constituents of the essential oil are 65% to 80% of 
 
cinnamaldehyde and lesser percentages of the other phenols and 
 
terpenes including eugenol , trans cinnamic acid ,hydroxy 
 
cinnamaldehyde , cinnamyl alcohol and its acetate ,limolene, 
 
alpha terpinol ,tannins ,mucilage ,oligomeric procyanidins and 
 
trace  amounts of coumarin 
 
Structure  
 
:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cinnamaldehyde Eugenol 
   
  
  Excipients profile 
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Apperence : Liquid 
Colour : Yellow 
Density :   1.03 g/ml at 25
o
 C 
Solubility :   Soluble in alcohol , insoluble in water 
Uses : Flavouring agent , germicide , fungicide , local stimulant , 
  aromatic,Astringent carminative 
   
  
  Excipients profile 
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PLURONIC F 127   
Synonyms : Polyethylene-propylene glycol copolymer 
Chemical name :    α-hydro-o-hydroxypoly(oxyethylene)poly (oxypropylene) 
   poly-(oxyethylene)  block copolymer 
Empirical formula : The poloxamer polyols are a series of closely related block 
  copolymers of ethylene oxide conforming to the general 
  formula 
Structural formula :  
 
 
 
 
 
 
 
 
 
 
Molecular weight 
Functional category 
Description 
 
 
 
 
 
 
 
 
 
 
: 
 
: 
 
 
 
: 
 
 
 
 
 
 
 
 
 
 
12500 daltons   
 
Non ionic surfactant ; emulsifying agent ;solubilising agent 
 
tablet lubricant ; anti foaming agent 
 
Pluronic F 127 generally occur as white ,waxy ,free 
 
flowing prilled granules or as cast solids .they are 
 
practically odourless and tasteless. 
   
  
  Excipients profile 
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MAGNESIUM STEARATE 
 
 
 
Description   :   Light white,very fine, precipitated or milled, impalpable powder 
of low bulk density, having a faint odour of stearic acid and a 
characteristic taste 
Synonyms :   Magnesium distearate, magnesium octadecanoate, acid,   
    magnesium salt, stearic acid, dibasic magnesium stearate 
Chemical Name             :   Octadecanoic acid magnesium salt 
 
 
 
Structural formula  
 
  
 
 
 
 
 
 
 
 
 
 
 
Molecular Weight 
 
 
 
 
 
 
 
 
 
 
 
: 591.24 g/mol
 
Molecular Formula 
 
: [CH2(CH2)16COO2]Mg 
 
Melting Point 
 
: 117-150° C
 
Solubility 
 
 
Stability and Storage 
 
 
Safety 
 
 
Related Substances 
 
: Slightly soluble in benzene and warm ethanol and practically not 
 
soluble in ethanol 
 
: Stable material and should be stored in a well closed dry container 
 
in a cool, dry place 
 
: Non toxic for oral administration and consuming higher quantity 
 
   will lead to produce laxative effect 
 
:  Calcium stearate, stearic acid, zinc stearate 
 
   
  
  Excipients profile 
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LACTOSE 
Synonyms 
Chemical name 
 
 
: Arose 25, milk sugar, lactosum mono hydricum  
 
monohydrate lactose. 
 
: D-(+)-lactose 1-hydrate , D- lactose mono hydrate 
Structural formula :  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecular formula : C12 H24 O12 
Molecular weight : 360.31g/mol 
Melting point : 215° C 
Solubility :   freely soluble in water, slightly soluble in alcohols 
  and insoluble chloroform. 
Stability :   keep container tightly closed in a cool well ventilated 
  area. 
Storage :   Do not store above 23° C 
Safety :   kept away from heat, sources of ignition and 
  oxidizing agents . Do not ingest or breathe dust. 
Related substances :   lactulose , alpha lactulose , alpha D- lactose monohydrate,spray 
  dried lactose, anhydrous lactose 
Application :   lactose is widely used as a filler or filler-binder in 
  pharmaceutical tablets by the direct compression method. 
   
  
  Excipients profile 
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TALC   
Synonyms : Talcum, stealite, shelleck 
Chemical name : Hydrous magnesium silicate 
Structural formula :  
 
 
 
 
 
 
 
 
 
 
 
Molecular weight : 379.27 g/mol 
Molecular formula :   H2 Mg3 O12 Si4 
Melting point : 800°C 
Solubility : Insoluble in water and ethanol, very slightly soluble in  mineral 
  Acids 
Stability and storage :   Talc is stable and store in dry place in well closed contained or 
  Bags 
Safety :   At levels of 1000mg/m
3
 ,talc is considered as immediately 
  dangerous to use and hazardous to health. 
Related to sustances : Hydrous magnesium silicate . 
Applications :   Anti-caking agents,coating agents,lubricating agents and release 
  agent, filler aid and dusting powder. 
   
  
  Excipients profile 
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DICALCIUM PHOSPHATE 
 
Synonyms                           :  calcium hydrogen phosphate, phosphoric acid ,calcium salt 
 
Appearance                        :  white granular powder 
 
Structural formula             :     
 
 
 
 
Molecular formula               :  CaHPO4 
 
Molecular weight                 :  172.03 g/mol 
 
Density                                  :  2.31 g/cm3 
 
Solubility                              : Soluble in ammonium citrate, citric acid, insoluble in water  
 
Storage                                 : Store at room temperature. 
 
Applications                        : Flowing agent, tablet filler, food additive, polishing agent,       
biomaterial                                                     
  Excipients profile 
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SPAN 60  
Molecular formula                  :    C24H46O6 
Chemical name                       :    Sorbitian monostearate 
Structural formula                 :       
                                                
Melting point                           :   57 ˚C 
Flash point                               :    >230 ˚F 
Molecular weight                    :   43.6 g/mol 
Solubility                                 :   Soluble in ethanol,isopropanol,vegetable oil and mineral oil  
                                                      Insoluble in water. 
Stability                                   :   Stable. combustible. incompatible with oxidizing agents 
Storage                                    :   Store below 30˚C 
  Materials and Instruments 
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                                                    MATERIALS & INSTRUMENTS  
Table 2.1: List of chemicals used  
INGREDIENTS VENDER 
Telmisartan Gifted sample 
Cinnamon oil S.D. Fine chemicals 
Polyethylene glycol 400 Sigma Aldrich 
Pluronic F 127 Sigma Aldrich 
Micro crystalline cellulose Sigma Aldrich 
Lactose.LR S.D.Finechemicals.ltd 
Magnesium stearate. LR Otto chemical reagents 
Talc.LR Lobachemie Ltd.,Mumbai 
Dicalcium Phosphate Sigma Aldrich 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Materials and Instruments 
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  LIST OF EQUIPMENT USED  
    Table 2.2: List of Equipments used 
Equipment Make and Model 
pH meter LI-120 , ELCO 
Compression Machine Rimek, 10 station, B- Tooling 
UV spectrometer UV 1650 PC SHIMADZU 
FT/IR spectrometer JASCO 4100-FT/IR , FT/IR 8400 Shimadzu 
Dissolution apparatus USP Dissolution apparatus paddle 2 
method-240V 
Centrifuge (ultra) EPPENDROF ,5415 R , GERMANY 
Magnetic stirrer 2MLH , REMI Insrument 
Bath sonicator Sonics – 230 10v 
Sieves Jayant scientific , Mumbai 
Electronic balance ELB 300 , shimadzu , Philippines 
Cyclo mixer CM 101 REMI 
Particle size and zeta potential analyzer MALVERN zeta sizer ZS90 
Phase contrast Microscopy Leica, S40 , 230 10 V, 5W 
Scanning Electron Microscope JEOL, Japan- JSM 6360 
 
 
  Preformulation Studies 
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PREFORMULATION STUDIES  
MELTING POINT    
A capillary tube was sealed with a Bunsen burner and it was filled with the drug telmisartan 
through the open end. The drug – filled capillary tube was placed in the melting point apparatus 
and temperature at which the drug started to melt was noted. 
SOLUBILITY STUDIES  
1g of the drug was dissolved in 1ml, 10ml, 30 ml and 100ml of various solvents depending upon 
its solubility. The resulting solubility was compared with the solubility limits specified in the 
Indian pharmacopeia  
DETERMINATION OF LAMBDA MAX  
10 mg of drug was dissolved in 10 ml of methanol to prepare stock solution – A of concentration 
1mg/ml. 1ml of stock-A was further diluted to 100 ml to get stock-B of concentration 20 mcg/ml. 
This solution was scanned from 200-400 nm in a UV spectrophotometer to determine the lambda 
max. 
STANDARD CURVE  
10mg of drug was dissolved in 100ml of methanol to get a stock solution –A of concentration 
100mcg/ml. 0.1ml of stock –A was diluted to 10 ml to give a stock – B. A serial dilutions of the 
stock-B were done to get solutions of concentrations 1, 2, 3, 4, 5, 6, 7,8 mcg/ml. These solutions 
were analyzed in the UV spectrophotometer at the 296 nm. A calibration curve was plotted with 
concentration on x-axis and the absorbance on the y-axis, the correlation coefficient was also 
calculated. 
 
 
 
 
 
 
 
 
 
  Preformulation Studies 
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STANDARD GRAPH  
The linearity was obtained between 1-10 mcg/ml of telmisartan and the regression value was 
found to be 0.99113 
Table 2: Calibration curve of Telmisartan  
 
         
       
Figure 9: Calibration curve of Telmisartan 
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METHODOLOGY 
 
Screening of components 
 
 
Solubility studies 
 
 
The solubility of Telmisartan in various oils, surfactants and co-surfactants was done by the 
vial shake method. An excess of drug was added to the vial containing 5ml of the 
oil/surfactant and was sealed with an aluminum foil. The sealed vial was heated at 40°C and 
then centrifuged at 15,000 rpm for 10 mins. The insoluble drug was removed by filtering it 
and the resulting solution was analyzed in the UV spectrophotometer. 
 
 
Emulsification study 
 
 
Surfactant 
 
 
300 mg of the surfactant was mixed with 300 mg of the selected oil, heated to 50°C and diluted 
to 50 ml with water. The ease of emulsification was observed by the number of flask inversions 
required for the formation of an emulsion. The prepared emulsions were analyzed in the UV 
spectrophotometer for their percentage transparence at 650 nm using distilled water as blank. 
They were also observed visually for any signs of phase separation or turbidity. 
 
 
Co-surfactant 
 
 
100 mg of co-surfactant, 200 mg of surfactant and 300 mg of the selected oil were taken 
and heated to 50°C and 300 mg of this mixture was diluted to 50 ml. This was assessed for 
the ease of emulsification by the above procedure. 
 
 
Pseudo ternary phase diagrams 
 
 
The surfactant and co-surfactant were mixed in different ratios and was added to oil phase 
in varying proportions. It was then titrated with water until the mixture turned clear. The 
values were then plotted in Chemix software to identify the nanoemulsification region 
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Preparation of SNEDDS 
 
 
The drug was weighed to 80mg and was mixed with the specified amount of oil. To this 
the specified amount of the surfactant and co surfactant were added. It was heated to 
40°C and sonicated for 15 mins, after which it was stored at room temperature. 
 
 
 
Table 3: Composition of Telmisartan SNEDDS formulation 
 
 
Formulation Drug (mg) Oil  (cinnamon Surfactant Cosurfactant 
code  oil) (ml) (PEG-400) (ml) (propylene 
    glycol) (ml) 
     
FT 1 1 0.3 0.5 0.2 
     
FT 2 1 0.2 0.3 0.5 
     
FT 3 1 0.5 0.3 0.2 
     
FT 4 1 0.2 0.4 0.4 
     
FT 5 1 0.4 0.2 0.4 
     
FT 6 1 0.3 0.5 0.2 
     
FT 7 1 0.3 0.3 0.4 
     
FT 8 1 0.5 0.2 0.3 
     
FT 9 1 0.4 0.4 0.2 
     
FT 10 1 0.2 0.5 0.3 
     
     
Formulation Drug (mg) Oil (cinnamon Span 60 (mg) Pluronic F 127 
code  oil )(ml)  (mg) 
     
FT 11 80 3 400 300 
     
FT 12 80 2 400 400 
     
FT 13 80 2 350 350 
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Brij – 72 was not used as surfactant because brij – 72 forms insoluble aggregates when 
preparing formulations 
 
T2, T4&T9 are selected based on formation of emulsion. After few days emulsion goes to 
instability due to improper selection of surfactants. Due to instability of emulsion 
cosurfactant was changed and replaced with pluronic F 127 because it has higher percentage 
of transmittance after propylene glycol. 
 
Conversion of liquid SNEDDS to solid SNEDDS: 
 
 
Liquid SNEDDS was taken and mixed with adsorbents avicel pH 101 until free flowing 
powder was obtained .The powder was then mixed with additives , dicalcium phosphate as 
binding agents in suitable proportions. 13 mm punch and die cavity were used for punching 
to yield self nanoemulsifying tablets of telmisartan. 
 
 
Evaluation parameters of liquid SNEDDS: 
 
 
Visual observation: 
 
 
The formulation were diluted and made to stand for 24 hours at 37° C. They were observed 
for phase separation and turbidity. 
 
 
Self-emulsification time: 
 
 
1ml of formulations was added to 100 ml of distilled water at 37° C being agitated at 
100 rpm. The time required for the formation of a milky emulsion was noted. 
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Table 4: Grades for the visual assessment of self nano emulsifying formulation 
 
 
 Grade Visibility 
   
 I Clear or slightly bluish white in appearance within I 
  Minute 
   
 II Slightly less clear ; bluish white in appearance < 2 
  minutes 
   
 III Milky in appearance within 3 minutes 
   
 IV Dull white which is slightly in appearance , slow to 
  emulsify > 3 minutes 
   
 V Turbid in appearance > 3 minutes 
   
Droplet size and zeta potential :  
 
 
1ml of formulation was diluted to 100 ml with distilled water and sonicated for 15 minutes .the 
resulting nano-emulsion was checked for droplet size and zeta potential in a particle size analyzer 
(Malvern zetasizer). The average droplet size and zeta potential was determined. 
 
 
Drug content: 
 
 
1ml of formulations were taken and diluted sufficiently .these solutions were then analyzed 
in the UV spectrophotometer. The drug concentration present was extrapolated from the 
standard graph. The drug content was calculated using the below formula. 
 
 
Drug content = concentration X dilution factor X correction factor X volume of formulation. 
 
 
Robustness to dilution: 
 
 
The formulations were diluted to 10 ml, 50 ml, and 100 ml and were observed over a period 
of 24 hours for phase separation or signs of precipitation. 
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Morphological studies: 
 
Scanning electron microscopy : The morphology and size of the prepared SNEDDS was 
observed by SEM .samples were fixed on a brass stub using double sided adhesive tape and 
were made electrically conductive by coating with a thin layer of gold and SEM images were 
recorded at 15 KeV accelerating voltage. 
 
 
EVALUATION OF SOLID – SNEDDS 
 
 
Micrometrics properties of s-SNEDDS of telmisartan 
 
Characterization of telmisartan loaded S-SNEDDS 
 
Angle of repose (θ) 
 
 
The angle of repose of S-SNEDDS was determined by funnel method. Accurately weighed 
sample were taken in afunnel. Height of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of S-SNEDDS powder. The powder was allowed 
to flow through funnel freely onto the surface. The diameter of thepowder cone was 
measured and angle of repose calculated using the following equation 
 
tan θ = h/r 
 
Where; h = height of the heap, r = radius of the heap 
 
 
Bulk and tapped density 
 
 
Both bulk density (BD) and tapped density (TD) were determined. A quantity of 2 g of S-
SNEDDS was introducedinto a 10 mL measuring cylinder. Initial volume was observed, and 
then the cylinder was allowed to fall under itsown weight onto a hard surface from a height of 
2.5 cm at 2 second intervals. The tapping was continued until nofurther change in volume 
was noted. Bulk density and tapped density were calculated using the following equations 
 
BD = Weight of powder / Bulk Volume 
 
 
TD = Weight of powder / Tapped Volume 
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Compressibility Index 
 
 
The compressibility of the S-SNEDDS granules was determined by Carr’s Compressibility 
Index as follow 
 
 
Carr’s Compressibility Index (%) = [(TD-BD) / TD] X 100 
 
 
Hausner ratio 
 
It is the ratio of tapped density to bulk density. It gives an idea about the flow characters of 
powder particles and can be calculated as follow 
 
 
Hausner ratio = TD / BD 
 
 
Evaluation of telmisartan SNE tablet: 
  
Weight variation 
 
10 tablets were selected randomly and weighed.The average weight was also seen. The 
weight variation between the individual weight and average weight was calculated. 
The weight variation should conform to the limits. 
 
Table 5: IP limits for weight variation 
 
 
Average weight of the tablet (mg) Maximum percentage deviation allowed 
 (%) 
  
<130 mg 10 
  
130-324 7.5 
  
>324 5 
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Hardness 
 
 
Tablet hardness is the force required foe breaking the tablet in a diametric compression test. 
A tablet was placed between the anvils of the tester and the crushing strength is noted . 
normal hardness ranges from 4-6 kg/cm
2 
 
Friability 
 
 
10 tablets were weighed and placed in a friabilator. It was operated at 25rpm for 4 mins or 
100 revolutions dropping the tablet from a 6 inch height during revolutions. The percentage 
friability was calculated by 
 
Percentage friability = (initial weight – final weight) / initial weight X 100 
 
 
Disintegration 
 
 
It is the time in which tablets will disintegrate into particles which will pass through a mesh 
screen size 10. The disintegration tester contains a basket a basket rack with 6 tube with 10 
mesh screen at the bottom. The basket is immersed in a medium at 37° C usually. 
 
 
 
 
IN-VITRO DISSOLUTION STUDIES 
 
 
Instrument : USP XXIV dissolution rate test apparatus 
Type : paddle type 
Medium : 0.1N HCL buffer pH 1.2 – 900 ml 
Temperature : 37 ± 0.5°C 
Testing time : 60 mins 
Sample withdrawal volume : 5 ml at specified intervals 
Sample : telmisartan S-SNE tablet 
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USP 24 paddle instrument (ELECTRO LAB TDT – 06 P) 
 
 
The dissolution of the tablets was performed in 0.1N HCL buffer pH 1.2 at 37° C at 75 rpm 
and a stirrer depth of 25mm. the sampling intervals were 5,10,15,30,45,60,75 and 90 minutes. 
5 ml of fresh buffer solution was replaced after each withdrawal. The sample was then 
filtered and analyzed spectrophotometrically. The experiments were performed in triplicate 
and the mean values are reported. 
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RESULTS AND DISCUSSIONS 
 
PREFORMULATION 
 
Melting point 
 
The melting point was found to be 272˚C which confirms the identification of the drug 
 
Solubility studies 
 
Solubility of  Telmisartan in different solvents are 
 
Water – insoluble 
 
Ethanol – slightly soluble 
 
Methanol – soluble 
 
Dissolves in 1M sodium hydroxide 
 
LAMBDA MAX 
 
The diluted stock which was scanned for maximum wavelength the peak at 296 nm .this 
was selected and was used for further studies 
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FT/IR data of Telmisartan 
 
Figure 10: FT-IR data of Telmisartan  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: FT- IR data of Telmisartan 
 
S.no Wave number cm
-1 
Assignment of group 
   
1 1460 Methyl C-H asymmetric 
  bond 
   
2 1408 Carboxylic acid 
   
3 1384 Aliphatic nitro compounds 
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FT/IR data of Pluronic F 127 
 
Figure 11: FT-IR data of Pluronic F 127  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: FT- IR data of Pluronic F 127 
 
S.No Wave Number cm
-1 
Assignment of group 
   
1 3362 O-H stretching 
   
2 2927 C-H stretch 
   
3 1455 C-H bend 
   
4 1299 C-O stretch 
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FT/IR Data of Microcrystalline cellulose 
 
Figure 12: FT-IR data of Microcrystalline cellulose  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: FT- IR data of Microcrystalline cellulose 
 
S.no Wave number cm
-1 
Assignment of group 
   
1 668 C-H bend 
   
2 1032 0-H stretching 
   
3 3565 Hydroxyl group,H bonded 
  O-H stretch 
   
4 1640 Aromatic combination bands 
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FT-IR DATA OF SPAN 60 
 
Figure 13: FT-IR data of Span 60  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: FT- IR data of span 60  
 
S.no Wave number cm
-1 
Assignment of group 
   
1 721 Aromatic C-H out plane bend 
   
2 1058 Alkyl substituted C-O stretch 
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FT – IR DATA DRUG + EXCIPIENTS 
 
Figure 14: FT-IR data of Drug&Excipients  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10: FT- IR data of Drug&Excipients 
 
 
S.no Wave number cm-1 Assignment of group 
   
1 3164 Normal polymeric OH 
  stretch 
   
2 1460 Methyl C-H asymmetric 
  bond 
   
3 3458 O-H stretch 
   
4 1640 Aromatic combination bands 
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STANDARD GRAPH 
 
The linearity was obtained between 1-10 mcg/ml of telmisartan and the regreesion value 
(r
2
) was found to be 0.99113 
 
 
 
 
Table 11: Calibration curve of Telmisartan 
 
 
Concentration Absorbance at 
(mcg/ml) 296 nm 
  
1 0.076 
  
2 0.296 
  
3 0.386 
  
4 0.493 
  
5 0.626 
  
6 0.748 
  
7 0.915 
  
8 1.064 
   
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure 15 : Calibration curve of Telmisartan 
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FORMULATION OF S-SNEDDS 
 
The components of the SNEDDS have to be selected with care in order to avoid precipitation 
of the drug during the shelf life. Therefore the solubility studies of Telmisartan in oils and 
surfactants were carried out. The results are shown in the figure. Telmisartan was highly 
soluble in cinnamon oil among the lipids, 25±1.43 mg ml. The various solubilities are depicted 
in the figure. 
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Table 12: Solubility studies in oil 
 
S NO Vehicle Solubility (mg/ml) 
   
1 Olive oil 7.21 
   
2 Cotton seed oil 8.36 
   
3 Cinnamon oil 25 
   
4 Corn oil 4.89 
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Figure 16: Solubility studies in oil 
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Screening of Surfactants 
 
300 mg of the surfactant was mixed with 300 mg of the selected oil, heated to 50°C and diluted to 
50 ml with water. The ease of emulsification was observed by the number of flask inversions 
required for the formation of an emulsion. The prepared emulsions were analysed in the UV 
spectrophotometer for their percentage transparence at 650 nm using distilled water as blank. 
 
They were also observed visually for any signs of phase separation or turbidity. Based on the 
percentage of transmittance surfactant has selected for formulation. Brij 72 forms insoluble 
aggregates so we select the propylene glycol, Span 60, PEG 400 and Pluronic f 127 
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Table 13: Percentage transmittance of surfactants 
 
Surfactant Percentage of transmittance 
  
Span 40 18.12 
  
Span 60 50.35 
  
Brij 72 63.7 
  
PEG 400 71.72 
  
Propylene glycol 80.61 
  
Pluronic f 127 66.65 
   
 
 
 
Percentage of transmittance 
 
90 
 
80 
 
70 
 
60 
 
50 
 
40 
 
30 
 
20 
 
10 
 
0  
span 40 span 60 brij 72 PEG 400 propylene pluronic f 127 
    glycol  
 
Surfactants 
 
 
Figure 17: Percentage Transmittance of surfactants 
 
Pseudoternary phase diagrams were constructed for identifying the self emulsifying regions. 
 
It gives us an idea of the changes a SNEDDS under goes when diluted with gastric fluids 
Larger the shaded area in the diagram, more the self emulsification ability. From each phase 
diagram different concentrations of oil, at which nanoemulsions formed, were selected at a 
difference of 5% (10, 15, 20, 25 and 30 ) so that maximum formulations could be selected for 
optimizing the best formulation. Another phase diagram was also plotted without water to give 
us an idea of the miscibility of the other 3 excipients. Better self emulsification was seen with 
concentrations of surfactant above 50% and oil below 30%. Above these concentrations either 
phase separation or turbidity was seen. 
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Figure 18: Pseudo Ternary phase diagram  
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Evaluation 
 
Visual assessment and self emulsification time 
 
Formulations FT-11,FT-12,FT-13showed no phase separation or turbidity. Formulations with 
concentrations of oil below 30% and surfactant above 70% showed SNEDDS that have good 
clarity and No phase separation. 
 
Visual assessment and self emulsification time 
 
In nano-emulsion formulations only FT-11, FT-12and FT-13 were clear. The rest of the 
formulations showed precipitation. 
 
Table 14: Visual assessment and self emulsification time of SNEDDS and S-SNEDDS 
 
formulations 
 
Formulation Visibility Grade Precipitation 
   
FT 1 ш Yes 
   
FT 2 ш No 
   
FT 3 ш Yes 
   
FT 4 ш No 
   
FT 5 ш Yes 
   
FT 6 ш Yes 
   
FT 7 ш Yes 
   
FT 8 ш Yes 
   
FT 9 ш No 
   
FT 10 ш Yes 
   
FT 11 ш No 
   
FT 12 ш No 
   
FT 13 ш No 
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Droplet size and Zeta potential 
 
The size of droplets after nanoemulsification is the most important factor as it affects the 
absorption of the drug as well as drug release. The smaller droplets have larger surface 
area thereby increasing the absorption. The size of droplets decreased with high 
concentration of either oil or surfactant. PDI is the ratio of standard deviation to the mean 
droplet size. It indicates the uniformity of size range in the formulation. Zeta potential 
denotes the charge of repulsion among the particles. A high zeta potential for small 
particles is indicative of better stability. The particle size of FT11, FT12 &FT13 range 
from 277nm,246nm&220 nm with PDI from 0.159, 0.385&0.395 
 
Table 15: Characterzation of S-SNEDDS formulations 
 
Formulation Particle Size (nm) PDI Zeta Potential   (mV) 
    
FT11 181 0.199 -0.118 
    
FT12 273 0.201 -4.44 
    
FT13 220 0.395 -6.49 
    
 
 
Robustness to dilution 
 
The formulations were diluted in various ratios to assess the performance of the S-SNEDDS 
in the body. The diluted S-SNEDDS showed no precipitation or phase separation indicating 
the stability of the nanoemulsions 
 
Self emulsification time: 
 
1ml of formulations was added to 100ml of distilled water at 37° C being agitated at 100rpm. 
The time required for the formation of a milky emulsion was noted for FT11, FT 12 &FT13 
were 83secs,94secs &77secs
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Particle size of FT11: 
 
  Figure 19: particle size of FT11 
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Particle size of FT12: 
 
Figure 20: particle size of FT 12 
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Particle size of FT13: 
 
Figure 21: Particle size of FT13 
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MORPHOLIGICAL STUDIES 
 
SCANNING ELECTRON MICROSCOPY 
 
Figure 22:SEM image of FT11 Figure 23:SEM image of FT12  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FT11 FT12 
 
Figure 24: SEM image of FT13  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FT13 
 
Conversion of liquid S-SNEDDS to solid form (SNE tablets) 
 
FT11 , FT12and FT13 were mixed with avicel PH 101 in varying amounts from 50mg – 500 
mg, yielded a free flowing powder that was further dried in the oven for 30 mins. For the 
tablet compression, the selected binders were Lactose and dicalcium phosphate. Tablets were 
punched with magnesium stearate and talc as lubricant. 
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DRUG CONTENT IN S-SNEDDS : 
 
100mg of nanoformulation was dissolved in 100ml of distilled water.From this 1ml was 
taken and made upto 10ml.further from this 1ml was taken and made upto 10ml and 
absorbance was taken at 294nm using UV-spectrophotometer. From this the required amount 
of nano formulation to be made into tablet and it is being calculated. 
 
Characterization of telmisartan S-SNEDDS: 
 
Micromeritic properties of S-SNEDDS: 
 
The values obtained for the angle of repose of the three formulae FT11,FT12 and FT13 after 
adding glidant were 32˚ϴ,33˚ϴ and 35˚ϴ.these values indicate that all formulae have good 
flowability .the bulk density of the thee formulae FT11,FT12 and FT13 was found to be 
0.29g/ml,0.27g/ml and 0.24g/ml respectively.however,tapped density was 0.32g/ml,0.33g/ml 
and 0.37g/ml.Carr ̓s index of formulae FT11,FT12 and FT13 was found to be 9.37,15 and 9 
respectively which give an indication about the good flowability of the three S-SNEDDS 
formulae.this was further supported by the values of Hausner ̓s ratio.the results of Hausner ̓s 
ratio of formulae FT11,FT12 and FT13 were 1.09,1.18 and 1.1 respectively. the improved 
flowability of S-SNEDDS formulae may be due to good sphericity of particles these three 
formulae goes for tablet compression. 
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Table 16: Micromeritics properties of SNE powder formulation 
 
Before adding glidant 
 
Formulation Bulk Tapped Carr ̓s index Hausner ̓s Angle of 
Code density density  ratio repose(ϴ) 
 (g/ml) (g/ml)    
      
FT11 0.22 0.35 34 1.5 45 
      
FT 12 0.23 0.33 30 1.4 45 
      
FT13 0.24 0.34 28 1.4 46 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17: Micromeritics properties of SNE powder formulation 
 
After adding Talc 2% 
 
Formulation Bulk Tapped Carr ̓s index Hausner ̓s Angle of 
code Density density (%) ratio repose (ϴ) 
 (g/ml) (g/ml)    
      
FT11 0.29 0.32 9.3 1.09 32 
      
FT12 0.27 0.33 15 1.18 33 
      
FT13 0.24 0.37 9 1.1 35 
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COMPRESSION OF TELMISARTAN SNE TABLET: 
 
Table 18: Compression of telmisartan SNE tablet  
 
 
 
 Telmisartan 20mg For 1 tablet: 
PUNCHING OF (excipients- Drug – 20 mg 
TELMISARTAN dicalcium phosphate/ Excipients- 
SNE – TABLET lactose / micro crystalline 113mg/100mg/190mg 
(FT 11) cellulose/magnesium Magnesium stearate 2% 
 stearate & talc Talc 1% 
 
 
 
 
 Telmisartan 20mg For 1 tablet: 
PUNCHING OF (excipients- Drug – 20 mg 
TELMISARTAN dicalcium phosphate/ Excipients- 
SNE – TABLET lactose / micro crystalline 102mg/110mg/170mg 
(FT 12) cellulose /magnesium Magnesium stearate 2% 
 stearate & talc Talc 1% 
 
 
 Telmisartan 20mg For 1 tablet: 
PUNCHING OF (excipients- Drug – 20 mg 
TELMISARTAN dicalcium phosphate/ Excipients- 
SNE – TABLET lactose /micro crystalline 123mg/100mg/190mg 
(FT 13) cellulose /magnesium Magnesium stearate 2% 
 stearate & talc Talc 1% 
   
Formulation FT11 Formulation FT12 Formulation FT13 
contains 87mg of contains 118mg of contains 77mg of 
telmisartan telmisartan telmisartan 
nanoformulation nanoformulation nanoformulation 
equivalent to 20mg of equivalent to 20mg of equivalent to 20mg of 
telmisartan pure drug telmisartan pure drug telmisartan pure drug 
(with excipients) (with excipients) (with excipients) 
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FT11 Telmisartan SNE tablets 
 
Figure 25: FT11 Telmisartan SNE tablets  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FT12 Telmisartan SNE tablets 
 
Figure 26: FT12 Telmisartan SNE tablets  
 
 
 
 
 
 
 
 
 
 
 
 
 
FT13 Telmisartan SNE tablets 
 
Figure 27: FT13 Telmisartan SNE tablets  
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Figure 28: Formulation of Telmisartan Liquid SNEDDS  
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Evaluation of Telmisartan SNE tablet: 
 
Weight variation test: 
 
Table 19: Weight variation test 
 
 
 
Formulation code Weight variation (%) 
  
FT11 3.8 
  
FT12 4.4 
  
FT13 4.5 
  
 
 
The percentage weight variation for all formulations was performed. All the formulations 
passed weight variation test as per the pharmacopeial limits of 5% as shown in the table above 
 
Friability test: 
 
Table 20: Friability test 
   
Formulation code  Friability (%) 
   
FT11  0.28 
   
FT12  0.24 
   
FT13  0.26 
   
 
 
The friability test for formulations was performed. All the formulations passed friability test 
as per the pharmacopeial limits as shown in the table. 
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Hardness test: 
 
Table 21: Hardness test 
 
Formulation code Hardness (Kg/cm
2
) 
  
FT11 5 
  
FT12 4 
  
FT13 5 
  
 
 
The hardness of formulations was carried out and found that it was 4 to 5 Kg/cm
2
 for formulations 
FT11, FT12 and FT13 are passed and within this limits as shown in the table above. 
 
 
 
Disintegration test: 
 
Table 22: Disintegration test 
 
 
 
Formulation code Disintegration time 
 (mins) 
FT11 4 
  
FT12 4 
  
FT13 6 
  
 
 
The disintegration test for all formulation was performed. All the formulations passed 
disintegration test as per the pharmacopeial limits as shown in the table. 
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Dissolution study 
 
Dissolution data of FT11 Telmisartan SNE tablet 
 
Table 23: Dissolution data of FT11 telmisartan SNE tablet 
 
Time (minutes) Absorbance Concentration Amount of Percentage of 
 (nm) (µg/ml) drug release (mg) drug release 
    (%) 
     
5 0.66 0.5 4.5 22.5 
     
10 0.79 0.6 5.4 27 
     
15 0.134 1 9 45 
     
30 0.162 1.2 10.8 54 
     
45 0.182 1.4 12.6 73 
     
 
 
 
 
Figure 29: Dissolution profile of FT11 SNE Telmisartan tablet  
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Dissolution data of FT12 Telmisartan SNE tablet 
 
Table 24: Dissolution data of FT12 Telmisartan SNE tablets 
 
 
 
Time (minutes) Absorbance Concentration Amount of Percentage of 
 (nm) (µg/ml) drug release (mg) drug release 
    (%) 
     
5 0.93 0.7 6.3 31.5 
     
10 0.107 0.9 8.1 40.5 
     
15 0.159 1.2 10.8 54 
     
30 0.184 1.4 12.6 63 
     
45 0.257 1.6 14.4 76 
     
 
 
Figure 30: Dissolution study of FT12 SNE Telmisartan tablets  
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Dissolution data of FT13 Telmisartan SNE tablet 
 
Table 25: Dissolution data of FT13 Telmisartan SNE tablet 
 
 
 
Time (minutes) Absorbance Concentration Amount of Percentage of 
 (nm) (µg/ml) drug release(mg) drug release 
    (%) 
     
5 0.070 0.6 5.4 27 
     
10 0.128 1 9 45 
     
15 0.133 1.1 9.9 49.5 
     
30 0.164 1.4 12.6 63 
     
45 0.211 1.6 14.4 72 
     
 
 
Figure 31: Dissolution profile of FT13 SNE Telmisartan tablets  
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Dissolution data of Telmisartan tablet- market formulation 
 
Table 26: Dissolution data of Telmisartan tablet- marketed formulation 
 
 
Time (minutes) Absorbance Concentration Amount of Percentage of 
 (nm) (µg/ml) 
drug 
release(mg) drug release 
    (%) 
     
5 0.022 0.1 0.9 4.5 
     
10 0.049 0.3 2.7 13.5 
     
15 0.098 0.7 6.3 31 
     
30 0.110 0.9 8.1 40.5 
     
45 0.174 1..3 11.7 58.5 
     
 
 
 
 
 
 
 
  
 
 
Figure 32: Dissolution profile of Telmisartan marketed tablets  
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SUMMARY AND CONCLUSION 
 
 
 
Oral route is the most convenient route of administration but it faces the problem of low oral 
bioavailability. Self nano emulsifying therapeutic system (SNETS) can be used to overcome 
the problems faced while using low aqueous soluble drugs. These systems form emulsion in 
situ with have good stability. This study aimed at investigating the increase in the 
bioavailability by administering a BCS class II drug, in a SNEDDS form and was compared 
to the conventional telmisartan tablets. 
 
It can be concluded from the experimental study carried out that the formulation of a poorly 
water soluble drug, telmisartan into Self Nanoemulsifying Drug Delivery System yields a 
formulation with nano size range & good zeta potential. The liquid was further made into 
tablet form for better stability. The prepared formulations were characterized for the size, zeta 
potential, self-emulsification time and drug content & compressed into tablets. 
 
The in vitro study of the best formulation FT12 SNE tablet showed 1.4 fold increase in the 
bioavailability when compared to the marketed formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
